Symbols

STOK

Stoke Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About STOK

Stoke Therapeutics, Inc.

A biotech company that develops antisense oligonucleotide medicines to target RNA splicing to enhance gene expression

Industry

Biological Technology

Established Date

Listing Date

06/19/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

170

Fiscal Year Ends

12-31

Website

www.stoketherapeutics.com

Security Type

Common stock

Office address

45 Wiggins Avenue, Bedford, MA 01730

Business

Introduction

Stoke Therapeutics, Inc., was founded in June 2014 and was incorporated under the laws of the State of Delaware. The company is a late-stage clinical enterprise focused on up-regulating protein expression through RNA drugs to address the underlying causes of serious diseases. With its proprietary TANGO (Targeted Enhanced Nuclear Gene Output) technology platform, the company is committed to developing antisense oligonucleotide drugs to selectively restore protein levels. Its leading drug in development, zorebunersen (STK-001), is a therapy with potential for disease modification and is currently in late-stage clinical trials for the treatment of severe progressive hereditary epilepsy, Dravet syndrome. The company focuses on diseases related to insufficiency of single dose as well as central nervous system and ophthalmological diseases, and its technology concept has been proof-of-concept in multiple biological systems. Led by a management team with extensive experience in the fields of human genetics, RNA regulation and rare disease drug development, the company continues to advance its pipeline of innovative therapies.

Company Financials

EPS

STOK has released its 2025 Q3 earnings. EPS was reported at -0.65, versus the expected -0.58, missing expectations. The chart below visualizes how STOK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

STOK has released its 2025 Q4 earnings report, with revenue of 1.40M, reflecting a YoY change of -93.80%, and net profit of -57.93M, showing a YoY change of -452.70%. The Sankey diagram below clearly presents STOK's revenue sources and cost distribution.